Balyasny Asset Management LLC Syndax Pharmaceuticals Inc Transaction History
Balyasny Asset Management LLC
- $58 Billion
- Q3 2024
A detailed history of Balyasny Asset Management LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Balyasny Asset Management LLC holds 367,177 shares of SNDX stock, worth $5.23 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
367,177Holding current value
$5.23 Million% of portfolio
0.01%Shares
9 transactions
Others Institutions Holding SNDX
# of Institutions
232Shares Held
90.1MCall Options Held
1.01MPut Options Held
692K-
Black Rock Inc. New York, NY7.91MShares$113 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.84MShares$83.3 Million9.23% of portfolio
-
Wellington Management Group LLP Boston, MA4.99MShares$71.1 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$69.6 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.11MShares$58.5 Million6.25% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $806M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...